Regulus Therapeutics Inc.
Regulus Therapeutics Inc. (RGLS): 2 pipeline candidates · ~19 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
18.8 months
D/E 0.08 · 0% dilution
Lead: Phase 1
2 candidates
N/A
N/A
A transparent, data-derived signal for Regulus Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$49.5M
Quarterly Burn
$10.6M
Runway
18.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| farabursen | Phase 1 |
| rgls8429 | Phase 1 |
Frequently asked questions
How many drug candidates are in Regulus Therapeutics Inc.'s pipeline?
Regulus Therapeutics Inc. (RGLS) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Regulus Therapeutics Inc.'s lead drug candidate?
Regulus Therapeutics Inc.'s most advanced tracked candidate is farabursen (Phase 1) for autosomal dominant polycystic kidney disease.
What is Regulus Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Regulus Therapeutics Inc. has approximately 18.8 months of cash runway.
Who is the CEO of Regulus Therapeutics Inc.?
Alice S. Huang is the chief executive officer of Regulus Therapeutics Inc. (RGLS).
Get the full picture on Regulus Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.